Aspen Neuroscience files for IPO, China proposes restrictions on biopharma acquisitions, and Lakefront sells CAR-T pipeline

Aspen Neuroscience files for IPO to advance Parkinson's cell therapy

San Diego-based Aspen Neuroscience has filed for an initial public offering (IPO) on the Nasdaq, seeking additional capital to advance its autologous cell therapy pipeline targeting Parkinson's disease and other neurological conditions.

The company's lead candidate, sasineprocel (ANPD001), uses induced pluripotent stem cells (iPSCs) derived from a patient's own skin cells, which are differentiated into dopamine-producing neuronal precursor cells before being transplanted into the brain. The approach aims to replace the dopamine-producing neurons lost through the progression of Parkinson's disease.

The filing follows encouraging Phase 1/2a clinical data reported earlier this year, which showed improvements across measures of motor function, symptom control and quality of life at 12 months following treatment. Proceeds from the proposed IPO would support the ongoing early-stage study and preparations for a Phase 3 trial, alongside the development of Aspen's earlier-stage microglia cell replacement programs.

Having raised approximately $347 million since its inception, including a $115 million Series C in November 2025, Aspen's decision to pursue a public listing comes amid renewed activity in the biotech IPO market. However, the company has also highlighted its need for substantial additional financing to sustain operations and progress its clinical pipeline.

Read more via BioPharma Dive

China proposes restrictions on foreign acquisitions of critical biopharma platforms

China is proposing new restrictions on the overseas transfer of key biopharmaceutical technologies, including proprietary cell and gene therapy platforms, as part of an update to its technology export control framework.

The draft policy would prohibit foreign acquisitions involving certain proprietary cell and gene therapy, small interfering RNA (siRNA), and pathogen gain-of-function platforms. It would also introduce approval requirements for the full transfer of proprietary drug target identification and verification technologies in cell and gene therapy and siRNA.

The proposal comes amid growing international interest in Chinese biotechnology assets, with the country's reported cross-border biopharma transaction value reaching $120 billion as of August 2026, representing a 36% year-on-year increase.

Importantly, the proposed restrictions distinguish between the transfer of platform ownership and conventional licensing arrangements. China's Ministry of Commerce has clarified that out-licensing agreements, alongside outsourced research and manufacturing services, would remain outside the scope of the proposed ban.

This distinction could limit the immediate impact on international biopharma dealmaking, where transactions have predominantly focused on individual therapeutic assets rather than the outright acquisition of underlying technology platforms.

Nevertheless, the proposal signals China's intention to retain greater domestic control over strategically important biomedical technologies as its position within the global biopharmaceutical innovation landscape continues to expand.

For international cell and gene therapy developers and investors, the proposed changes introduce an additional consideration when evaluating cross-border acquisitions, platform partnerships and long-term business development strategies.

Read more via Fierce Biotech

Lakefront Biotherapeutics sells preclinical CAR-T portfolio to Armed Cell Therapeutics

Lakefront Biotherapeutics, formerly known as Galapagos, has completed the sale of its preclinical CAR-T portfolio to Belgium-based Armed Cell Therapeutics (ACT), providing a new development pathway for the assets following Lakefront's decision to exit cell therapy.

Under the agreement, Lakefront will receive an upfront payment of €8 million, with the potential for up to $230 million in additional milestone payments and low-single-digit royalties. The acquired portfolio comprises next-generation multi-targeting and armed CAR-T constructs originating from AboundBio, which Galapagos acquired in 2022. The programs are designed to improve CAR-T potency and persistence while addressing mechanisms of treatment resistance across hematological malignancies and solid tumors.

The transaction includes two lead candidates approaching clinical development, targeting non-Hodgkin lymphoma and small cell lung cancer, alongside three additional early-stage research programs. ACT was established by former Galapagos CEO Paul Stoffels, alongside John Mellors and Peter Verhaeghe, and will independently advance the acquired assets.

The agreement provides continuity for the former Galapagos CAR-T programs while allowing Lakefront to concentrate its resources on its revised development strategy. It also offers a potential route for shareholders to benefit from the future progression of the divested assets through milestone and royalty payments.

Read more via Globe Newswire and BioPharma Dive